Scotland Okays First ILAP Drugs For Reimbursement
Executive Summary
The Scottish Medicines Consortium has recommended Gilead’s Trodelvy, Amgen’s Lumykras and Pfizer’s Lorviqua for use on the Scottish National Health Service.
You may also be interested in...
Reimbursement Rejection On Cost Grounds For “Highly Effective” Trodelvy In England
In a draft decision NICE, the health technology appraisal body for England and Wales, has declined to recommend Gilead’s Trodelvy for triple negative breast cancer patients.
UK Should Look To France To Speed Up Access To Innovative Medicines
Gilead suggests that the UK could take lessons from France on rapidly making innovative new treatments available after approval.
UK Regulator Issues 41 ‘Innovation Passports’ In First Year Of New Pathway
The UK’s ILAP, a post-Brexit scheme introduced in 2021 to accelerate the development of, and access to, new innovative medicines, proved popular in its first year of operation. A total of 71 applications were received last year from companies wanting to take advantage of the regulatory advice, tools and flexibilities on offer.